Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Open-label, Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria and Active Hemolysis

Next Previous
Search
Trial Profile

A Multi-center, Randomized, Open-label, Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria and Active Hemolysis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Iptacopan (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals

    • Most Recent Events

    • 13 Dec 2022 Results of integrated analysis of X2201 and X2204 studies evaluating dose exposure response relationships of biomarkers and efficacy measures to support dose selection for iptacopan presented at the 64th American Society of Hematology Annual Meeting and Exposition
    • 05 Apr 2022 Status changed from active, no longer recruiting to completed.
    • 14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top